Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
GLOBETECH PUBLISHING

Powder Developed to Enhance NMR Signals for Faster, Better Structure Determination and Early Cancer MRI Diagnosis

By BiotechDaily International staff writers
Posted on 22 Jan 2014
Image: Schematic of polarization process: Polarizing Agent (powder) (left), Molecule (red), Microwave (top), Nuclear Magnetic Resonance (bottom), Hyperpolarization of the targeted molecule (left) (Photo courtesy of the University of Lyon, France).
Image: Schematic of polarization process: Polarizing Agent (powder) (left), Molecule (red), Microwave (top), Nuclear Magnetic Resonance (bottom), Hyperpolarization of the targeted molecule (left) (Photo courtesy of the University of Lyon, France).
Dynamic nuclear polarization (DNP) combined with nuclear magnetic resonance (NMR) allows, due to polarizing agents, the enhancement of NMR signals from a wide range of molecules resulting in the substantial reduction of the NMR acquisition time. It reveals, therefore, strong advantages over conventional NMR and possibly over X-ray diffraction techniques used to characterize proteins on synchrotron type equipment.

NMR spectroscopy is an extremely powerful nondestructive technique for the characterization of molecules. Widely used by chemists from its early beginnings, it is now essential in the synthesis and analysis laboratories and its scope extends into biologic laboratories.

NMR has also known an exciting new advance in the medical field with the development of magnetic resonance imaging (MRI). Up to now, the DNP has been effectively applied to MRI for the early diagnosis of tumors in small animals (pigs and rodents) in preclinical research and more recently to 30 human patients having prostate cancers. However, MRI using DNP cannot be generalized to human diagnosis because polarizing agents used to activate biologic tracers/contrast agents need to be quantitatively separated from the polarized solution before human injection and image acquisition. This technical hurdle is now solved.

In this framework, an innovative powder for the easy polarization of many molecules, including biologic tracers, was developed in the frame of a European collaboration involving the University of Lyon’s laboratory of chemistry, catalysis, polymers and processes (UMR 5265-LC2P2), the European Center for High-Field NMR (UMR 5280, CRMN; Lyon, France) and ETH (Swiss Federal Institute of Technology) Zurich (Switzerland). These novel powders are creating tools for the fast characterization of complex systems by means of solid state NMR using DNP but also in the field of medical imaging for early cancer diagnosis using MRI. In this latter field, these agents can deliver a solution of polarized biologic tracers/contrast agents that are free from any impurity and therefore safe to inject in humans.

The research was published August 2013 in Journal of the American Chemical Society.

Related Links:

University of Lyon
European Center for High-Field NMR
ETH Zurich



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: To adhere to catheters and start urinary tract infections, bacteria extend microscopic fibers with sticky proteins at their ends. Researchers have developed a vaccine that blocks the EbpA protein, visible as a white bulge above, and stops infections in mice (Photo courtesy of Dr. John Heuser, Washington University School of Medicine).

Blocking Binding of Bacteria to Fibrinogen Prevents Biofilm Formation and Catheter-Associated Bladder Infection in Mice

A team of molecular microbiologists has identified and targeted a critical step in biofilm formation and developed a vaccine that prevents catheter-associated urinary tract infections in mice.... Read more

Drug Discovery

view channel
Image: S-649266 has more robust antibacterial activity than established antibiotics against multidrug-resistant bacteria (Photo courtesy of Shionogi).

Novel Antibiotic Shows Potential for Broad Range of Infections

The emergence of bacterial resistance to known antibacterial agents is becoming a major challenge in treating the infection caused by multi drug resistant (MDR) bacteria. In order to treat bacterial... Read more

Business

view channel

Collaboration of Mayo Clinic and IBM Cognitive Computer Devised to Improve Clinical Trial Research

The Mayo Clinic (Rochester, MN, USA) and IBM (Armonk, NY, USA) recently announced plans to pilot Watson, the IBM cognitive computer, to match patients more rapidly with suitable clinical trials. A proof-of-concept phase is currently ongoing, with the intent to introduce it into clinical use in early 2015.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.